

P&T Motion History Statins

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<i>Individual Statins</i> atorvastatin fluvastatin fluvastatin ER lovastatin lovastatin ER pitavastatin pravastatin rosuvastatin simvastatin	After considering the evidence of safety, efficacy and special populations, I move that the following statins are safe and efficacious: pitavastatin, atorvastatin, fluvastatin, fluvastatin ER, lovastatin, lovastatin ER, pravastatin, rosuvastatin, and simvastatin and can be subjected to therapeutic interchange in the Washington Preferred Drug List. The PDL must include at least one high potency option (atorvastatin and/or rosuvastatin) and the PDL must include pravastatin as an alternative with minimal cytochrome P450 drug interactions.	April 20, 2016	Yes Bowman Chew	Yes Rowe Harvey	Passed unanimous
<i>Combination Products</i> atorvastatin/ ezetimibe lovastatin/ niacin ER simvastatin/ ezetimibe simvastatin/ niacin ER	I move to not include the combination products as part of the statin drug class on the PDL.				